approach to the preparation of α-diazo-β-ketosulfones from sulfonyl chlorides is described. It involves the conversion of the sulfonyl chloride to sodium sulfinate, alkylation of the latter with α-haloketones followed by diazo transfer using the ‘sulfonyl-azide-free’ (‘SAFE’) protocol in aqueous medium. The simple and expedient method relies on readily available starting materials and provides facile
Studies on the Chemistry and Reactivity of α-Substituted Ketones in Isonitrile-Based Multicomponent Reactions
作者:Lijun Fan、Ashley M. Adams、Jason G. Polisar、Bruce Ganem
DOI:10.1021/jo8019708
日期:2008.12.19
Using the Passerini and Ugi reactions as representative tests, the utility of several alpha-substituted ketones R-CO-CH(2)-X (X = sulfonyloxy, acyloxy, azido, halo, hydroxy, and sulfonyl) in isonitrile-based multicomponent reactions was explored. In a relative rate study (R = PhCH(2)CH(2)), each of the alpha-substituted ketones underwent Passerinicondensation more rapidly than the parent ketone. Short
A Cu‐catalyzed cascade oxidative radical process of β‐keto sulfones with alcohols has been achieved by using oxygen as an oxidant. In this reaction, β‐keto sulfones were converted into sulfinate esters under the oxidative conditions via cleavage of C−S bond. Experimental and computational studies demonstrate that a new pathway is involved in this reaction, which proceeds through the formation of the
Multicomponent Reactions as a Powerful Tool for Generic Drug Synthesis
作者:Cédric Kalinski、Hugues Lemoine、Jürgen Schmidt、Christoph Burdack、Jürgen Kolb、Michael Umkehrer、Günther Ross
DOI:10.1055/s-0028-1083239
日期:2008.12
Multicomponent reactions (MCRs) are not only a powerful tool for drug discovery, they also represent an excellent methodology for synthesis rationalization. Here we wish to illustrate the potential of MCRs in the production of generic drugs by synthesizing, in racemic form, the antiplatelet agent clopidogrel and the non-steroidal antiandrogen bicalutamide, using Ugi, Petasis and Passerini reactions.
The present invention relates to Kv1.3 potassium channel blockers of Formula (I) and their use in the treatment of autoimmune and inflammatory diseases.